Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicocodine SCHEMBL1023092 | 1.00 | OPRM1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicocodine SCHEMBL159020 | 1.00 | OPRM1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL26237 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL680036 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL29408441 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL29349768 | 0.94 | OPRD1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL1649977 | 0.93 | OPRD1 (0.68) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL395672 | 0.93 | OPRD1 (0.68) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8418756 | 0.91 | OPRM1 (0.76) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8769499 | 0.87 | OPRM1 (0.75) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827651-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-28 | — | — | US | claimed |
| US-12570707-B2 | Codon-optimised complement factor I | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| CN-119876200-A | Codon optimized complement factor I | 陀螺仪治疗有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113383011-B | Codon optimized complement factor I | 陀螺仪治疗有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4386085-A2 | CODON-OPTIMISED COMPLEMENT FACTOR I | Gyroscope Therapeutics Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| US-11827651-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3588634-B1 | IMPROVED ORGANIC ELECTRODE MATERIAL | INNOVATIONLAB GMBH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-4229076-A1 | NUCLEIC ACID ENCODING AN ANTI-VEGF ENTITY AND A NEGATIVE COMPLEMENT REGULATOR AND USES THEREOF FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Gyroscope Therapeutics Limited (GB) | 2023-08-23 | — | — | EP | disclosed |
| US-20230212275-A1 | NUCLEIC ACID ENCODING AN ANTI-VEGF ENTITY AND A NEGATIVE COMPLEMENT REGULATOR AND USES THEREOF FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Gyroscope Therapeutics Limited (GB) | 2023-07-06 | — | — | US | disclosed |
| CN-115927412-A | Codon optimized complement factor I | 陀螺仪治疗有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022079453-A1 | NUCLEIC ACID ENCODING AN ANTI-VEGF ENTITY AND A NEGATIVE COMPLEMENT REGULATOR AND USES THEREOF FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Gyroscope Therapeutics Limited (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-20220073576-A1 | CODON-OPTIMISED COMPLEMENT FACTOR I | Gyroscope Therapeutics Limited (GB) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570707-B2 | Codon-optimised complement factor I | CFH, CFB, CFD | OPRM1 2792/4885OPRK1 2974/4885OPRD1 2144/4885 |
| US-11827651-B2 | Organic electroluminescent materials and devices | SSB, L1CAM, LEF1 | OPRM1 777/4885OPRK1 1266/4885OPRD1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.